{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:23:44Z","timestamp":1781810624814,"version":"3.54.5"},"reference-count":63,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"FCT Portugal","doi-asserted-by":"publisher","award":["UIDB\/04046\/2020"],"award-info":[{"award-number":["UIDB\/04046\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT Portugal","doi-asserted-by":"publisher","award":["UIDP\/040467\/2020"],"award-info":[{"award-number":["UIDP\/040467\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT Portugal","doi-asserted-by":"publisher","award":["2018 Research Scholars"],"award-info":[{"award-number":["2018 Research Scholars"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT Portugal","doi-asserted-by":"publisher","award":["LOPES21I0"],"award-info":[{"award-number":["LOPES21I0"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences USA","doi-asserted-by":"publisher","award":["UIDB\/04046\/2020"],"award-info":[{"award-number":["UIDB\/04046\/2020"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences USA","doi-asserted-by":"publisher","award":["UIDP\/040467\/2020"],"award-info":[{"award-number":["UIDP\/040467\/2020"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences USA","doi-asserted-by":"publisher","award":["2018 Research Scholars"],"award-info":[{"award-number":["2018 Research Scholars"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences USA","doi-asserted-by":"publisher","award":["LOPES21I0"],"award-info":[{"award-number":["LOPES21I0"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation USA","doi-asserted-by":"publisher","award":["UIDB\/04046\/2020"],"award-info":[{"award-number":["UIDB\/04046\/2020"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation USA","doi-asserted-by":"publisher","award":["UIDP\/040467\/2020"],"award-info":[{"award-number":["UIDP\/040467\/2020"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation USA","doi-asserted-by":"publisher","award":["2018 Research Scholars"],"award-info":[{"award-number":["2018 Research Scholars"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation USA","doi-asserted-by":"publisher","award":["LOPES21I0"],"award-info":[{"award-number":["LOPES21I0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The R334W (c.1000C&gt;T, p.Arg334Trp) is a rare cystic fibrosis (CF)-causing mutation for which no causal therapy is currently approved. This mutation leads to a significant reduction of CF transmembrane conductance regulator (CFTR) channel conductance that still allows for residual function. Potentiators are small molecules that interact with CFTR protein at the plasma membrane to enhance CFTR-dependent chloride secretion, representing thus pharmacotherapies targeting the root cause of the disease. Here, we generated a new CF bronchial epithelial (CFBE) cell line to screen a collection of compounds and identify novel potentiators for R334W-CFTR. The active compounds were then validated by electrophysiological assays and their additive effects in combination with VX-770, genistein, or VX-445 were exploited in this cell line and further confirmed in intestinal organoids. Four compounds (LSO-24, LSO-25, LSO-38, and LSO-77) were active in the functional primary screen and their ability to enhance R334W-CFTR-dependent chloride secretion was confirmed using electrophysiological measurements. In silico ADME analyses demonstrated that these compounds follow Lipinski\u2019s rule of five and are thus suggested to be orally bioavailable. Dose\u2013response relationships revealed nevertheless suboptimal efficacy and weak potency exerted by these compounds. VX-770 and genistein also displayed a small potentiation of R334W-CFTR function, while VX-445 demonstrated no potentiator activity for this mutation. In the R334W-expressing cell line, CFTR function was further enhanced by the combination of LSO-24, LSO-25, LSO-38, or LSO-77 with VX-770, but not with genistein. The efficacy of potentiator VX-770 combined with active LSO compounds was further confirmed in intestinal organoids (R334W\/R334W genotype). Taken together, these molecules were demonstrated to potentiate R334W-CFTR function by a different mechanism than that of VX-770. They may provide a feasible starting point for the design of analogs with improved CFTR-potentiator activity.<\/jats:p>","DOI":"10.3390\/jpm13010102","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T02:12:48Z","timestamp":1672625568000},"page":"102","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Additive Potentiation of R334W-CFTR Function by Novel Small Molecules"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-3329","authenticated-orcid":false,"given":"Mafalda","family":"Bacalhau","sequence":"first","affiliation":[{"name":"Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7335-6997","authenticated-orcid":false,"given":"Filipa C.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8062-5558","authenticated-orcid":false,"given":"Iris A. L.","family":"Silva","sequence":"additional","affiliation":[{"name":"Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-2220","authenticated-orcid":false,"given":"Camilla D.","family":"Buarque","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro 22541-041, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-8630","authenticated-orcid":false,"given":"Margarida D.","family":"Amaral","sequence":"additional","affiliation":[{"name":"Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-9359","authenticated-orcid":false,"given":"Miqu\u00e9ias","family":"Lopes-Pacheco","sequence":"additional","affiliation":[{"name":"Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine","volume":"10","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in epithelial physiology","volume":"74","author":"Gray","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/JEP.S255377","article-title":"Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis","volume":"13","author":"Pinto","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Yu","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","article-title":"Discovery of CFTR modulators for the treatment of cystic fibrosis","volume":"16","author":"Pedemonte","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Silva, I.A.L., Laselva, O., and Lopes-Pacheco, M. (2022). Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis. J. Pers. Med., 12.","DOI":"10.3390\/jpm12081321"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"Munck","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Hadida","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"36639","DOI":"10.1074\/jbc.M112.393637","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner","volume":"287","author":"Eckford","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Munck","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_18","unstructured":"(2022, October 10). ECFS Patient Registry Annual Report 2020. Available online: https:\/\/www.ecfs.eu\/sites\/default\/files\/ECFSPR_Report_2020_v1.0%20%2807Jun2022%29_website.pdf."},{"key":"ref_19","unstructured":"(2022, October 10). Relat\u00f3rio do Registro Brasileiro de Fibrose C\u00edstica 2019. Available online: http:\/\/portalgbefc.org.br\/ckfinder\/userfiles\/files\/REBRAFC_2019.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/362160a0","article-title":"Mutations in CFTR associated with mild-disease-form CI- channels with altered pore properties","volume":"362","author":"Sheppard","year":"1993","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1085\/jgp.118.4.407","article-title":"CFTR: Covalent and noncovalent modification suggests a role for fixed charges in anion conduction","volume":"118","author":"Smith","year":"2001","journal-title":"J. Gen. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-54158-2","article-title":"Nanomolar-potency \u2018co-potentiator\u2019 therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants","volume":"9","author":"Phuan","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.10.011","article-title":"Mutation-specific dual potentiators maximize rescue of CFTR gating mutants","volume":"19","author":"Veit","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1073\/pnas.1215982110","article-title":"Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle","volume":"110","author":"Jih","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jcf.2018.05.010","article-title":"Combination potentiator (\u2018co-potentiator\u2019) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators","volume":"17","author":"Phuan","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3389\/fphar.2018.01221","article-title":"Identification and characterization of novel CFTR potentiators","volume":"9","author":"Gees","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/bph.15709","article-title":"A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR","volume":"179","author":"Liu","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00018-004-4422-3","article-title":"Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains","volume":"62","author":"Moran","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drudis.2015.08.004","article-title":"Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries","volume":"21","author":"Wang","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.drudis.2017.05.014","article-title":"The 1,2,3-triazole ring as a bioisostere in medicinal chemistry","volume":"22","author":"Bonandi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejmech.2016.02.041","article-title":"Synthesis of newer 1,2,3-triazole linked chalcone and flavone hybrid compounds and evaluation of their antimicrobial and cytotoxic activities","volume":"113","author":"Kant","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2015.01.003","article-title":"Synthesis and biological evaluation of phenyl-1H-1,2,3-triazole derivatives as anti-inflammatory agents","volume":"59","author":"Kim","year":"2015","journal-title":"Bioorg. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00044-013-0762-6","article-title":"Design, synthesis, and antiviral activity of new 1H-1,2,3-triazole nucleoside ribavirin analogs","volume":"23","author":"Ferreira","year":"2014","journal-title":"Med. Chem. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1021\/jm1000979","article-title":"N -((1-benzyl-1 H -1,2,3-triazol-4-yl)methyl)arylamide as a new scaffold that provides rapid access to antimicrotubule agents: Synthesis and evaluation of antiproliferative activity against select cancer cell lines","volume":"53","author":"Stefely","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2018.07.029","article-title":"1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: Their anti-proliferative & anti-inflammatory activity","volume":"81","author":"Naaz","year":"2018","journal-title":"Bioorg. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bioorg.2018.10.003","article-title":"Design, synthesis, structural characterization and in vitro evaluation of new 1,4-disubstituted-1,2,3-triazole derivatives against glioblastoma cells","volume":"83","author":"Colombo","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_38","first-page":"1258","article-title":"New \u03b1-Hydroxy-1,2,3-triazoles and 9H-Fluorenes-1,2,3-triazolesSynthesis and Evaluation as Glycine Transporter 1 Inhibitors","volume":"31","author":"Silva","year":"2020","journal-title":"J. Braz. Chem. Soc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"175396","DOI":"10.1016\/j.ejphar.2022.175396","article-title":"Identification of novel F508del-CFTR traffic correctors among triazole derivatives","volume":"938","author":"Bacalhau","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lopes-Pacheco, M., Bacalhau, M., Ramalho, S.S., Silva, I.A.L., Ferreira, F.C., Carlile, G.W., Thomas, D.Y., Farinha, C.M., Hanrahan, J.W., and Amaral, M.D. (2022). Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A. Cells, 11.","DOI":"10.3390\/cells11010136"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1113\/jphysiol.2005.096669","article-title":"Failure of cAMP agonists to activate rescued \u0394F508 CFTR in CFBE41o- airway epithelial monolayers","volume":"569","author":"Bebok","year":"2005","journal-title":"J. Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-61779-117-8_2","article-title":"V High-throughput screening of libraries of compounds to identify CFTR modulators","volume":"741","author":"Pedemonte","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: The rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"114133","DOI":"10.1016\/j.bcp.2020.114133","article-title":"Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR","volume":"180","author":"Silva","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ebiom.2014.12.005","article-title":"Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis","volume":"2","author":"Awatade","year":"2015","journal-title":"EBioMedicine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/358761a0","article-title":"Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive","volume":"358","author":"Denning","year":"1992","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1042\/BJ20071420","article-title":"Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones","volume":"410","author":"Varga","year":"2008","journal-title":"Biochem. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"25636","DOI":"10.1074\/jbc.M115.671925","article-title":"Combination of Correctors Rescue \u0394F508-CFTR by Reducing Its Association with Hsp40 and Hsp27","volume":"290","author":"Boinot","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1021\/acs.jmedchem.0c01796","article-title":"Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic Fibrosis","volume":"64","author":"Kelgtermans","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.aaw7611","article-title":"Structural identification of a hotspot on CFTR for potentiation","volume":"364","author":"Liu","year":"2019","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1085\/jgp.201912360","article-title":"Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770","volume":"151","author":"Yeh","year":"2019","journal-title":"J. Gen. Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1085\/jgp.201711886","article-title":"A common mechanism for CFTR potentiators","volume":"149","author":"Yeh","year":"2017","journal-title":"J. Gen. Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/chem.201805919","article-title":"Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809","volume":"25","author":"Doiron","year":"2019","journal-title":"Chemistry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2002774","DOI":"10.1183\/13993003.02774-2020","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator","volume":"57","author":"Laselva","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"00716","DOI":"10.1183\/23120541.00716-2021","article-title":"Novel CFTR modulator combinations maximise rescue of G85E and N1303K in rectal organoids","volume":"8","author":"Ensinck","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcf.2017.06.002","article-title":"Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor","volume":"17","author":"Flume","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Silva, I.A.L., Railean, V., Duarte, A., and Amaral, M.D. (2021). Personalized Medicine Based on Nasal Epithelial Cells: Comparative Studies with Rectal Biopsies and Intestinal Organoids. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050421"},{"key":"ref_61","first-page":"2201800172","article-title":"Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants","volume":"2","author":"Vonk","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2201341","DOI":"10.1183\/13993003.01341-2022","article-title":"Rectal organoid-guided CFTR modulator therapy restores lung function in a CF patient with the rare 1677delTA\/R334W genotype","volume":"60","author":"Mitropoulou","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ciciriello, F., Bijvelds, M.J.C., Alghisi, F., Meijsen, K.F., Cristiani, L., Sorio, C., Melotti, P., Fiocchi, A.G., Lucidi, V., and De Jonge, H.R. (2022). Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers. J. Pers. Med., 12.","DOI":"10.3390\/jpm12040632"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/1\/102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:55:44Z","timestamp":1760118944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/1\/102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jpm13010102"],"URL":"https:\/\/doi.org\/10.3390\/jpm13010102","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]}}}